Our Board of Directors

Mark joined Quotient as Chief Executive Officer in 2005 and has over 25 years’ experience in the pharmaceutical and biotech industry. He has worked in a range of organizations including large multinational pharmaceutical companies through to private venture funded biotechnology companies.

Following his PhD (Biochemistry, University of Edinburgh) and post-doctoral research (Biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the U.K. During this time he was responsible for discovery projects across a number of therapeutic areas. Mark then joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to pre-clinical development. He returned to the U.K. with Incyte Pharmaceuticals to head up European Business Operations and was responsible for leading that organisation to record levels of performance. Prior to joining Quotient, Mark was the Chief Business Officer at Oxagen, a U.K. biotech company focused on novel therapeutics for Respiratory diseases.

Des has significant experience as a CFO in both private and public companies.

Mr. Glassell has more than 25 years of experience in the pharmaceutical industry with a focus on the production of biologic and chemical active pharmaceutical ingredients, drug product manufacturing and medical devices.  

Mr. Glassell has been a director of the board at Cambrex since 2016 and currently serves as non-executive chairman of the board of LSNE Contract Manufacturing. From 2011 to 2015, he was CEO of CMC Biologics, a contract manufacturing organization focused on biologic pharmaceuticals.

Previously, he held senior positions and served on the boards of several public and private life sciences companies, including Vitrolife AB, Cellartis AB, Nobel Chemicals, Berol Nobel, Cerus, CMC Biologics, Swedish American Chamber of Commerce, and the Swedish Chemical Industry Association.

Kasper focuses on investment opportunities in the Healthcare sector at Permira.

Since joining Permira, he has worked on a number of transactions including Corin, Quotient Sciences and Arcinova as well as being part of the monitoring team of Corin Group. Prior to joining Permira, Kasper worked for Goldman Sachs in London, and prior to that, Novo Holdings’ Principal Investments team in Copenhagen.

Kasper has his a Master’s degree in Applied Economics and Finance from Copenhagen Business School, Denmark.

Dimitrios focuses on investment opportunities in the Healthcare sector.

Prior to joining Permira, he worked for Onex for three years, where he was in charge of Healthcare investments in Europe. Prior to that, he spent nine years with BC Partners.

Henry focuses on investment opportunities in the Healthcare sector and has worked on numerous transactions including Atrium, BakerCorp, Cambrex, Genesys, Intelligrated, Intelsat, Jet Aviation and LSNE.

Prior to joining Permira, Henry spent five years at The Cypress Group, a US private equity firm, where he completed a number of buy-out transactions. He has also worked at Salomon Brothers in the investment banking division and in the Distressed Debt group of LibertyView Capital Management, a multi-strategy hedge fund.

Henry has a degree in Finance from Georgetown University, USA, and an MBA from Harvard Business School, USA.

Dimitrios holds a Master of Science in Corporate Finance from Bocconi University, Italy, and has an MBA from Harvard Business School, USA.